EA201990011A1 - Производное глюкагона, конъюгат на его основе, содержащая их композиция и их терапевтическое применение - Google Patents

Производное глюкагона, конъюгат на его основе, содержащая их композиция и их терапевтическое применение

Info

Publication number
EA201990011A1
EA201990011A1 EA201990011A EA201990011A EA201990011A1 EA 201990011 A1 EA201990011 A1 EA 201990011A1 EA 201990011 A EA201990011 A EA 201990011A EA 201990011 A EA201990011 A EA 201990011A EA 201990011 A1 EA201990011 A1 EA 201990011A1
Authority
EA
Eurasian Patent Office
Prior art keywords
conjugate
basis
composition
glucagon derivative
therapeutic application
Prior art date
Application number
EA201990011A
Other languages
English (en)
Inventor
Чон Гук Ким
Юн Джин Пак
Ин Юнг Чой
Сун Юб Чун
Original Assignee
Ханми Фарм. Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ханми Фарм. Ко., Лтд. filed Critical Ханми Фарм. Ко., Лтд.
Priority claimed from PCT/KR2017/006922 external-priority patent/WO2018004283A2/ko
Publication of EA201990011A1 publication Critical patent/EA201990011A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Abstract

Изобретение относится к производному глюкагона, конъюгату на его основе, содержащей их композиции и к их терапевтическому применению и, в частности, применению в отношении метаболического синдрома, гипогликемии и врожденного гиперинсулинизма.
EA201990011A 2017-06-02 2017-06-29 Производное глюкагона, конъюгат на его основе, содержащая их композиция и их терапевтическое применение EA201990011A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170069217 2017-06-02
PCT/KR2017/006922 WO2018004283A2 (ko) 2016-06-29 2017-06-29 글루카곤 유도체, 이의 결합체, 및 이를 포함하는 조성물, 및 이의 치료적 용도

Publications (1)

Publication Number Publication Date
EA201990011A1 true EA201990011A1 (ru) 2019-06-28

Family

ID=66998684

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990011A EA201990011A1 (ru) 2017-06-02 2017-06-29 Производное глюкагона, конъюгат на его основе, содержащая их композиция и их терапевтическое применение

Country Status (1)

Country Link
EA (1) EA201990011A1 (ru)

Similar Documents

Publication Publication Date Title
CO2019003182A2 (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
CL2023001909A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
CL2016002269A1 (es) Moduladores alostéricos del núcleo proteico de la hepatitis b.
CL2015000942A1 (es) Compuestos de benceno sustituido.
CY1121881T1 (el) Φαρμακοτεχνικη μορφη που περιεχει σταθερη αναλογια ινσουλινης glargine/λιξισενατιδης
EA202191513A1 (ru) Снижение вязкости фармацевтических составов
CO2017006898A2 (es) Formulación de relación fija de insulina glargina/lixisenatida
CL2016003023A1 (es) “compuestos derivados de (bencil-piperazin-1-il)(tetrahidrofuran-carbonil o tetrahidropiran-carbonil) sustituido, moduladores rorg; composición farmacéutica que los comprende; y su uso en el tratamiento de la esclerosis múltiple y espondilitis anquilosante”. pct
EA201791716A1 (ru) Фармацевтический состав
AR103323A1 (es) Derivados de glucagón
EA201692569A1 (ru) Полимиксины с низкой степенью замещения и композиции, их содержащие
EA201892376A1 (ru) Комбинированный состав трех противовирусных соединений
EA201990011A1 (ru) Производное глюкагона, конъюгат на его основе, содержащая их композиция и их терапевтическое применение
EA202091403A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
MA44558A1 (fr) Dérivé du glucagon, conjugué de celui-ci, composition le comprenant et utilisation thérapeutique de celui-ci
CR20190161A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terpéutico del mismo
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
CL2023000971A1 (es) Esteroides y conjugados de proteínas de los mismos.
EA201991993A1 (ru) Применение фенилкреатина в качестве ноотропного агента
IT201700002235A1 (it) Composizione per somministrazione orale utile nel trattamento del diabete e delle sindrome metaboliche in genere
EA201991733A1 (ru) Фармацевтические композиции для комбинированной терапии
UA118032U (uk) Фармацевтична композиція
EA201791296A1 (ru) Состав с постоянным соотношением инсулин гларгин/ликсисенатид
RU2014151103A (ru) Применение соединений класса 1,3,4-тиадиазина и их фармацевтической композиции с аскорбиновой кислотой в качестве средства коррекции экспериментального аллоксанового сахарного диабета